<DOC>
	<DOCNO>NCT01743001</DOCNO>
	<brief_summary>Clinical study ass efficacy , safety , tolerability macitentan subject Eisenmenger Syndrome .</brief_summary>
	<brief_title>Clinical Study Evaluate Effects Macitentan Exercise Capacity Subjects With Eisenmenger Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Eisenmenger Complex</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Subjects : participate hemodynamic substudy : male female ≥ 12 year age . participate hemodynamic substudy : male female ≥ 18 year age . Subjects ( include Down Syndrome [ DS ] ) confirm Eisenmenger Syndrome [ ES ] ( European Society Cardiology [ ESC ] European Respiratory Society [ ERS ] guideline ) : 1 . Established echocardiography : Large congenital shunt defect atrial , ventricular arterial level* right leave shunt bidirectional shunt prevalent right leave direction . 2 . Resting peripheral oxygen saturation ( SpO2 ) ≤ 90 % &gt; 70 % ( pulse oximetry , room air ) . The low limit 65 % subject living altitude great 2500 sea level . *Subjects follow open defect eligible study either isolate defect combination : atrial septal defect ( ASD ) ventricular septal defect ( VSD ) partial complete atrioventricular septal defect ( AVSD ) patent ductus arteriosus ( PDA ) aortopulmonary window ( AP window ) total partial anomalous pulmonary venous return ( TAPVR , PAPVR ) The defect may either unoperated previously palliate surgically ( provide significant residual defect remain ) . The Steering Committee review echocardiography data subject ( main study sub study ) confirm eligibility prior Randomization . Subjects follow finding cardiac catheterization : Mean rest pulmonary arterial pressure ( mPAP ) &gt; 25 mmHg Pulmonary capillary wedge pressure ( PCWP ) mean leave atrial pressure ( LAP ) leave ventricular end diastolic pressure ( LVED ) ≤ 15 mmHg Pulmonary vascular resistance ( PVR ) ≥ 800 dyn∙s/cm5 ≥ 10 Wood unit Subjects WHO functional class ≥ II . Subjects able reliably perform 6minute walk test ( 6MWT ) minimum distance 50 maximum distance 450 m. Main study hemodynamic substudy : Any following condition previously know identified via cardiac catheterization echocardiography : Pulmonary arterial venous stenosis &gt; 25 % size native pulmonary artery ( PA ) pulmonary vein Severe tricuspid regurgitation set leave right shunt ventricular atrial level Greater mild tricuspid stenosis Intracavitary RV outflow obstruction Greater mild mitral stenosis Intracavitary LV outflow obstruction Subvalvular supravalvular aortic stenosis Aortic coarctation Greater moderate mitral regurgitation Recognized extracardiac systemic venous collateral pulmonary venous circulation Recognized hepatic wedge pressureinferior vena cava pressure gradient &gt; 12 mm Hg PCWP `` v '' wave &gt; 20 mmHg Tetralogy Fallot Truncus arteriosus Interrupted aortic arch Transposition great artery Single ventricle defect : absent AV connection ( mitral tricuspid atresia ) , double inlet AV connection leave right ventricle , functional univentricular heart ( unbalanced AVSD , hypoplastic RV , double outlet RV ) , hypoplastic leave heart syndrome Ebstein 's anomaly Severe aortic regurgitation Pulmonary atresia PAPVR TAPVR , ONLY lung hypoplasia documentation confirm absence lung hypoplasia exist . For subject participate hemodynamic substudy follow also consider exclusion criterion : SVC stenosis &gt; 25 % size native vessel PDA , AP window , TAPVR , PAPVR , ASD sinus venosus anomalous pulmonary vein Down Syndrome Subjects deterioration clinical status within 3 month prior Screening Screening period . Known moderatetosevere restrictive ( i.e. , total lung capacity [ TLC ] &lt; 60 % predict value ) obstructive lung disease ( i.e. , force expiratory volume one second [ FEV1 ] &lt; 80 % predict value , FEV1 / force vital capacity [ FVC ] &lt; 70 % ) Treatment prostanoids within 1 month prior Randomization Subjects initiate PDE5 inhibitor within 1 month prior Randomization PDE5 inhibitor dose stable within 1 month prior Randomization Treatment endothelin receptor antagonist ( ERAs ) within 1 month prior Randomization Subjects initiate diuretic within 1 week prior Randomization subject whose diuretic treatment stable least 1 week prior Randomization Subjects consider organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>exercise capacity</keyword>
	<keyword>Eisenmenger Syndrome</keyword>
</DOC>